HSBC Upgrades Labcorp to Buy From Hold
HSBC has upgraded its rating for Labcorp from Hold to Buy, setting a price target of $40.
Stocks · News reference
Lunit Announces Collaborative Studies with Labcorp and CellCarta
Lunit will present two collaborative studies involving Labcorp and CellCarta at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mizuho Securities Adjusts Labcorp Price Target
Mizuho Securities has updated its price target for Labcorp Holdings Inc. to $400 from $355.
Labcorp CFO Julia Wang to Speak at UBS Global Healthcare Conference
Labcorp announced that Chief Financial Officer Julia Wang is scheduled to participate in a fireside chat at the upcoming UBS Global Healthcare Conference.
8-K filing — LABCORP HOLDINGS INC. (LH)
Filed: 2026-11-04 AccNo: 0000920148-26-000227 Size: 154 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Labcorp Holdings Insider Sold Shares Worth $389,395
An insider at Labcorp Holdings Inc. sold shares of the company's stock valued at $389,395, according to a recent SEC filing.
Barclays Maintains Labcorp Holdings at Equal-Weight, Raises Price Target to $380 from $330
Barclays has maintained its Equal-Weight rating on Labcorp Holdings while increasing its price target to $380 from $330.